Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study.

Angiogenesis
Steven KroonJohannes J Mager

Abstract

The inhibiting effects of itraconazole, an antifungal drug on vascular endothelial growth factor (VEGF) have recently been discovered. By inhibiting VEGF, itraconazole has shown potential in clinical trials as anti-cancer treatment. In hereditary hemorrhagic telangiectasia (HHT) patients, VEGF levels are elevated and inhibition of VEGF can decrease bleeding. Itraconazole could potentially serve as anti-angiogenic therapy for HHT-related bleeding. We report a proof of concept study with HHT patients and severe epistaxis. Patients were treated with daily 200 mg orally administered itraconazole for sixteen weeks. Twenty-one HHT patients, 8 females (38%), 13 males (62%), median age of 59 years (interquartile range (IQR) 55-69) were enrolled. Of these patients, 13 (62%) were diagnosed with HHT type 1, seven (33%) with HHT type 2 and in one patient (5%), no pathognomonic HHT mutation was found. Four patients (19%) prematurely terminated the study (3 due to mild or moderate side-effects) resulting in 17 patients included in the analyses. The median epistaxis severity score significantly decreased during treatment from 6.0 (IQR 5.1-7.2) to 3.8 (IQR 3.1-5.2) (p = 0.006). The monthly epistaxis frequency decreased from 56 to 38 epistaxis ...Continue Reading

References

Apr 6, 2000·American Journal of Medical Genetics·C L ShovlinH Plauchu
Jun 14, 2001·Lancet·S R AhmadB G Leissa
Aug 2, 2002·The Laryngoscope·Rahul K ShahStanley M Shapshay
Nov 2, 2004·Human Genetics·T G W LetteboerJ K Ploos van Amstel
Apr 17, 2007·ACS Chemical Biology·Curtis R ChongJun O Liu
Jan 21, 2010·The Laryngoscope·Jeffrey B HoagChristian A Merlo
Sep 8, 2011·Cancer Research·Blake T AftabCharles M Rudin
Mar 8, 2012·JAMA : the Journal of the American Medical Association·Sophie Dupuis-GirodFrédéric Faure
Feb 14, 2013·The Laryngoscope·B Maneesha SilvaClaire L Shovlin
Apr 3, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Charles M RudinJun O Liu
May 7, 2013·Expert Opinion on Drug Metabolism & Toxicology·Jodi Lestner, William W Hope
Sep 7, 2016·JAMA : the Journal of the American Medical Association·Sophie Dupuis-GirodFrédéric Faure
Sep 7, 2016·JAMA : the Journal of the American Medical Association·Kevin J WhiteheadJames R Gossage
Sep 14, 2016·Journal of Cell Communication and Signaling·Chandran S AbhinandPerumana R Sudhakaran
Jan 25, 2017·Health and Quality of Life Outcomes·Roberto ZarrabeitiaJosé Antonio Parra
Jan 28, 2017·Scientific Reports·Michiru NishitaYasuhiro Minami
Aug 10, 2017·Oncology Letters·Hiroshi TsubamotoTakashi Sonoda
Sep 8, 2018·Angiogenesis·Marie E FaughnanDennis L Sprecher

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

GraphPad
SPSS

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
Fabio PagellaElina Matti
© 2021 Meta ULC. All rights reserved